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Abstract 
Two patients presented with dyspnea and signs of chronic pancreatitis. Patient B had 
pleural effusion on chest X-ray. Patient A developed pleural effusion during the course of 
disease. On further analysis these pleural effusions showed elevated amylase 
concentrations. This finding suggested the diagnosis of a pancreaticopleural fistula 
which was confirmed by magnetic resonance cholangiopancreatography. Because of the 
distinct localization of the fistulas the patients were treated differently. In patient A an 
endoprosthesis was successfully placed in the pancreatic duct, and patient B underwent 
distal pancreatic resection. Considering the rarity of pancreaticopleural fistula, there is 
no consensus on diverse aspects of treatment, such as length of treatment with 
octreotide. However, a rationale for the distinction between fistulas suited for treatment 
with endoprosthesis or surgery seems to provide some grip. 
 
Introduction 
A pancreaticopleural fistula is a rare complication of chronic pancreatitis. In the 
literature various therapeutic modalities have been described: inhibition of the exocrine 
function of the pancreas with drugs (octreotide), endoscopic stenting of the pancreatic 
duct, and surgical removal of (part of) the pancreas. In this case report we present two 
patients and discuss the various therapies in more detail.  
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Cases 
Patient A 
A 58-year-old man with a history of a situs inversus totalis, alcohol abuse, hypertension and 
peripheral vascular disease came to the emergency ward with abdominal pain since three weeks. 
Physical examination showed no abnormalities besides local abdominal pain during palpation of the 
epigastric region. Blood samples showed the following values: WBC 23.5 × 10
9/l (4–10 × 10
9/l), 
thrombocytes 467 × 10
9/l (150–400 × 10
9/l), albumin 28 g/l (35–50 g/l), alkaline phosphatase 233 IU/l 
(<120 IU/l), γ-GT 145 IU/l (<55 IU/l), LDH 232 IU/l (<250 IU/l), SGPT 86 IU/l (<40 IU/l), SGOT 
62 IU/l (<35 IU/l), total bilirubin 14 μmol/l (<17 μmol/l), amylase 336 IU/l (<50 IU/l), triglyceride 
1.97 mmol/l (0.6–2.2 mmol/l), CRP 192 mg/l (<10 mg/l). A chest X-ray showed a situs inversus totalis 
without signs of pleural effusion. The patient was admitted under suspicion of acute pancreatitis. 
Ultrasonography of the abdomen showed a circumscriptive loculation of fluid around the liver. An 
additional abdominal CT scan showed intracapsular fluid loculation in the liver and no abnormalities of 
the pancreas (fig. 1). The loculated fluid was aspirated with ultrasonography guidance revealing 
1,600 ml green-yellow fluid. The bilirubin level in this fluid was 7 μmol/l and showed no bacterial 
growth; amylase levels where not determined. After aspiration epigastric pain subsided and the patient 
was discharged.  
A week later he returned to the emergency department with dyspnea and pain in the upper right 
quadrant and flank. Physical examination showed a breathing frequency of 45/min and a saturation of 
97% without supportive oxygen. Percussion of the thorax was muffled from the basis of the thorax until 
the sixth thoracic vertebra on the left side. Inherently there were no breathing sounds on auscultation. 
The abdomen was supple, but on palpation there was pain in the right upper quadrant. New blood 
samples revealed the following: WBC 19.0 × 10
9/l (4–10 × 10
9/l), thrombocytes 447 × 10
9/l (150–400 × 
10
9/l), alkaline phosphatase 176 IU/l (<120 IU/l), γ-GT 90 IU/l (<55 IU/l), LDH 282 IU/l (<250 IU/l), 
SGPT 64 IU/l (<40 IU/l), SGOT 43 IU/l (<35 IU/l), total bilirubin 15 μmol/l (<17 μmol/l), amylase 
464 IU/l (<50 IU/l), CRP 385 mg/l (<10 mg/l). Chest X-ray showed elevation of the left hemidiaphragm 
accompanied by some bilateral atelectasis and pleural effusion. The patient was readmitted under 
suspicion of having a relapse of the fluid loculation in the liver possibly complicated by an infection. 
Ultrasonography of the abdomen confirmed the suspicion, showing a relapse of the fluid collection 
which was drained at once. The obtained fluid showed the following values: bilirubin 10 μmol/l, WBC 
116.7 × 10
9/l, albumin 7 g/l, total protein 19 g/l, LDH 24,696 IU/l, amylase 40,782 IU/l. More than 1,000 
colonies of Streptococcus milleri were cultured. One day following the drainage the patient developed 
respiratory insufficiency and was admitted to the intensive care unit. He developed a vast amount of 
pleural effusion on the right side which was drained by thoracocentesis. The highest level of amylase in 
the pleural effusion was 70,584 IU/l. In this effusion no bacteria were isolated. Subsequently a magnetic 
resonance cholangiopancreatography (MRCP) was performed where a fistula was identified originating 
from the proximal pancreatic duct and ending in a fluid collection located adjacent to the diaphragm. 
This fluid collection had a close relation to the intracapsular fluid collection in the liver (fig. 2). The 
high levels of amylase in the fluid collection in the liver and in the pleural effusion strongly suggested 
that there was a continuum between the identified pancreatic fistula, the pleural cavity and the fluid 
collection in the liver. Octreotide therapy was started to inhibit the exocrine function of the pancreas. 
Already antibiotics were administered since the culture had grown Streptococcus. Since the fistula had 
its origin in the proximal pancreatic duct, an endoprosthesis was placed covering the origo by 
endoscopic retrograde cholangiopancreatography. After long-term admission of 28 days in the ICU the 
patient was transferred to the surgical ward. Slowly his clinical condition improved and he was 
discharged to a nursing home for revalidation 43 days after the endoprosthesis was placed. 
Patient B 
Patient B was a 58-year-old male. In the past he had been hospitalized several times for alcohol 
abuse-induced gastritis and dehydration. Two months prior to presentation at our hospital he had been 
analyzed elsewhere for complaints of dyspnea. A large volume of pleural effusion had been drained 
containing an elevated concentration of amylase A. CT scan of the abdomen was performed showing 
pseudocysts in the upper left quadrant. Recurrent complaints of dyspnea were the reason to consult our 
hospital. In addition to the dyspnea he reported abdominal pain in the upper right quadrant for several 
years which had increased markedly during the last few weeks. At the time of presentation the patient 
had been sober for a prolonged period. On physical examination we saw a cachectic man not looking 
acutely ill. Blood samples revealed the following values: white blood cell count (WBC) 8.9 × 10
9/l (4– 
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10 × 10
9/l), thrombocytes 455 × 10
9/l (150–400 × 10
9/l), albumin 37 g/l (35–50 g/l), alkaline phosphatase 
103 IU/l (<120 IU/l), γ-GT 28 IU/l (<55 IU/l), LDH 178 IU/l (<250 IU/l), SGPT 7 IU/l (<40 IU/l), SGOT 
20 IU/l (<35 IU/l), total bilirubin 6 μmol/l (<17 μmol/l), amylase 438 IU/l (<50 IU/l), CRP 11 mg/l 
(<10 mg/l). Plain chest radiography revealed a substantial amount of left-sided pleural effusion. Under 
suspicion of pancreatitis the patient was admitted to the hospital, the pleural effusion thought to be 
either reactive or caused by a pancreaticopleural fistula. The amylase level in the drained pleural 
effusion was 16,065 IU/l. Focal pancreatitis of the tail was seen on MRCP. The distal pancreatic duct was 
deformed and a fistula tract was identified communicating with one of the pseudocysts (fig. 3). This 
pseudocysts lay in close relation with the left hemidiaphragm and expansion to the pleural cavity was 
suspected. Following these findings octreotide therapy was started. After multidisciplinary deliberation 
the choice was made to perform a distal pancreatectomy. Perioperatively the clinical diagnosis of 
pancreatitis with pseudocysts was confirmed. A fistula was identified originating from one of the 
pseudocysts and ending at the hiatus aortae. Considering the extent of the pseudocysts and the 
pancreatitis infiltrate a splenectomy was also performed. The postoperative course was uneventful and 
the patient was discharged after eight days. 
Discussion 
Pancreaticopleural fistulas are a rare complication of chronic pancreatitis. The 
incidence in series described in the literature lies between 0.4 and 4.5% of patients having 
pancreatitis [1, 2]. Fistulas can arise following trauma or surgical procedure of the 
pancreas. The pathophysiological mechanism in chronic pancreatitis most probably 
consists of leakage from a pseudocyst or rupture of the pancreatic duct [3]. Most of the 
patients have a history of alcohol abuse (70–100%). Age at diagnosis varies from 20 to 
60 years (95%) [4]. 
Dyspnea, coughing and thoracic pain are the predominant symptoms in 
pancreaticopleural fistulas. Only 24% of the patients have accompanying abdominal pain 
[5]. In the described cases both patients had abdominal symptoms, however the 
pulmonary complaints were the most prominent. Pleural effusions frequently recur after 
drainage and are localised unilateral (left-sided) in 76% of the cases [6]. 
When patients have signs of chronic pancreatitis accompanied by pleural effusion, the 
possibility of a pancreaticopleural fistula must always be considered. Although it is an 
uncommon entity, the diagnosis can be made fairly easily by determining the 
concentration of amylase in pleural effusion [4]. Radiological imaging is available to 
sustain the diagnosis. MRCP seems to be the imaging modality of choice because of its 
superiority to CT in indentifying a fistula in the pancreatic region. Its noninvasive 
character is an advantage compared to endoscopic retrograde cholangiopancreatography 
[7, 8]. 
The first line of treatment options in pancreatic fistulas is the inhibition of the exocrine 
function of the pancreas by octreotide. The use of octreotide in gastrointestinal fistulas 
proved to reduce the time until closure and morbidity [9]. Specific rates of successful 
closure for pancreaticopleural fistulas have not yet been reported, however positive effects 
have been demonstrated [10]. The expanding knowledge of the pathogenesis of chronic 
pancreatitis has led to the identification of new molecular targets and subsequent 
therapeutic agents which might also prove beneficial in pancreatic fistulas. However, until 
now there are no reports of trials in humans reproducing the beneficial effect found in 
animal models [11]. Besides pharmacological intervention thoracocentesis is 
recommended. There is no consensus whether or not measures must be taken to prevent 
food and fluids passing the duodenum. Lamme et al. for instance advise enteral feeding 
through a nasojejunal tube [4], Safadi and Marks advise total parenteral nutrition [12], 
whereas Dhebri and Ferran consider neither of these measures meaningful [3]. The  
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duration of treatment with octreotide until the point it should be considered unsuccessful 
is also subject of debate. In general a period of 3–4 weeks is accepted [13]. Despite 
adequate drainage and treatment with octreotide there was no clinical improvement in 
patient A. Therefore an endoprosthesis was placed in the pancreatic duct. The positive 
effect of this procedure is not only attributed to the direct covering of the origin of the 
fistula, but also to the decrease in pressure in the pancreatic duct [3, 13, 14]. The 
distinction between fistulas suited for treatment with endoprosthesis and those requiring 
surgery is of great importance. The following three characteristics of the fistula are the 
limitations to the use of endoprosthesis. First the orirgin of the fistula must not be located 
in the distal segment of the pancreatic duct, second the duct must not be totally ruptured, 
and third there must be no obstruction of the duct leading to the impossibility to place a 
stent. If patients do not have these limitations, the rate of success with endoprosthesis is 
high [3, 13–16]. There is no uniform opinion on how long the endoprosthesis should rest 
in place, there are reports ranging from 4 weeks up to 6 months [6, 12]. For the remaining 
patients surgical intervention is the appropriate treatment option [17]. Patient B 
underwent a distal pancreatectomy and splenectomy since the fistula was located in the 
distal part of the pancreatic duct. The lack of long-term follow-up for treatment with 
endoprosthesis as well as for surgery is the reason no accurate data are available on the 
recurrence of either treatment. The follow-up treatment with octreotide is again subject of 
discussion, recommendations ranging from a few weeks to several months [9]. 
Conclusion 
Pancreaticopleural fistulas are a rare condition, but need to be considered in every 
patient with signs of chronic pancreatitis and pleural effusion. The diagnosis can be made 
by determination of the amylase concentration in pleural effusion and can be confirmed 
by MRCP. Having diagnosed a patient with a pancreaticopleural fistula, octreotide is the 
obvious treatment to start with. If the symptoms do not subside the placement of an 
endoprosthesis or surgical intervention might be appropriate. The choice of either of 
these treatment modalities depends on the characteristics of the fistula, such as location or 
extent. 
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Fig. 1. Patient A: Coronal image of a CT scan depicting the fluid collection in the liver. 
 
 
 
Fig. 2. Patient A: Coronal image of a MRCP depicting the fistula originating from the proximal 
pancreatic duct ending in a pseudocyst located just below the diaphragm. 
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Fig. 3. Patient B: Axial MRCP image showing the deformed distal pancreatic duct and the fistula and 
the close relation with the pseudocysts. 
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